At the news
? NEUTRALIMPACT 2/10 3 filed Nov 5, 2026 at 16:39 ET
Neera Clase, the new Chief Commercial Officer of Tarsus Pharmaceuticals, filed a Form 3 initial statement of beneficial ownership, disclosing 14,800 shares of common stock, options to purchase 76,861 shares at various exercise prices, and 12,105 restricted stock units. This is a routine filing required upon becoming an officer and provides no new financial or strategic information.
- Neera Clase appointed Chief Commercial Officer of Tarsus Pharmaceuticals, Inc.
- Filed Form 3 on 2026-11-05, reporting 14,800 shares of common stock owned directly.
- Holds options to purchase 23,000 shares at $25.56, 18,701 at $19.59, 14,909 at $15.00, 9,119 at $35.50, 6,126 at $44.54, and 5,007 at $74.90.
- Holds 2,864, 3,080, 3,014, and 3,147 restricted stock units (RSUs) with various vesting schedules starting March 15, 2027.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access